查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983707

免疫查核点抑制剂市场：按适应症、作用机制、给药途径和最终用户分類的全球市场预测，2026-2032年

Immune Checkpoint Inhibitors Market by Indication, Mechanism Of Action, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，免疫查核点抑制剂市场价值将达到 486.4 亿美元，到 2026 年将成长至 520.6 亿美元，到 2032 年将达到 844.5 亿美元，年复合成长率为 8.19%。

主要市场统计数据
基准年 2025 486.4亿美元
预计年份：2026年 520.6亿美元
预测年份 2032 844.5亿美元
复合年增长率 (%) 8.19%

这本内容全面的执行指南和入门指南提供了有关免疫查核点疗法的临床进展、监管变化和策略挑战的背景资讯。

免疫肿瘤学正迈入一个新时代，免疫查核点抑制剂已成为多种固体癌治疗模式的基础，而与之相关的商业性和临床生态系统也正在快速发展。本篇概要概述了查核点抑制剂疗法的现状，重点在于临床里程碑、监管先例以及先进生物製药面临的营运挑战。透过整合这些要素，企业领导者将更清楚地了解驱动研发、生产和商业化决策的相互关联的动态。

科学、临床实践、监管和管理的新创新正在重新定义免疫查核点抑制剂的开发和应用。

免疫查核点抑制剂领域正经历一系列变革性转变，涵盖科学发现、临床实践和商业策略。基于生物标记的患者筛选技术的进步以及对肿瘤微环境异质性的深入理解，使得靶向PD-1、PD-L1和CTLA-4的治疗方法能够更精准地应用。同时，查核点抑制剂与标靶治疗、细胞毒性疗法或新型免疫调节剂的联合治疗正在树立新的疗效标桿，并重塑标准治疗方案。这些进展要求申办方和医疗服务提供者重新评估临床试验设计、医保报销谈判以及真实世界数据（RWE）的收集和分析。

分析 2025 年美国关税措施对生物製药。

如果2025年推出新的关税措施或提高现有关税，可能会对免疫查核点抑制剂的整个价值链产生累积影响，尤其考虑到生技药品生产和原料采购的全球化特性。对原材料、一次性耗材、特殊层析法树脂或资本设备征收关税可能会增加原料药生产和填充/表面处理工程的接收成本。加上现有的物流限制和不断增长的产能需求，此类前置作业时间的影响可能导致更长的交货週期、更高的营运成本，并更加强调短期生产力计画。

从适应症、作用机制、最终用户和给药途径等方面进行多维细分，以辅助临床和商业决策。

在免疫查核点抑制剂领域，以细分市场为导向的观点能够为产品策略、临床开发和商业规划提供最实用的见解。在评估适应症时，必须认识到其范围涵盖膀胱癌、头颈癌、恶性黑色素瘤、非小细胞肺癌和肾细胞癌。此外，恶性黑色素瘤和非小细胞肺癌在治疗方案中可分为第一线和第二线治疗，每个治疗阶段还可细分为联合治疗和单药治疗。这些适应症层面的区分直接影响临床试验的受试者入组标准、对照组的选择和适应症定位，并影响不同肿瘤类型对应的支付方预期。

美洲、欧洲、中东和非洲以及亚太地区的市场细微差别和战略重点将决定产品上市和进入策略。

区域趋势对临床试验设计、监管策略、製造地选择和商业化路径均有显着影响。在美洲，监管体系和支付方结构强调快速进入和差异化价值交付，而生产和供应链的韧性通常与国内生产能力和监管预期相符。在该地区运作的相关人员通常优先考虑与当地监管机构和支付方相契合的临床终点，并倾向于采用真实世界数据（REW）计画来支持长期价值论点。

企业层面的竞争：免疫肿瘤学领域的合作、製造投资与产品差异化策略趋势。

免疫查核点抑制剂领域的公司策略呈现出多元化的特点，既有资金雄厚的成熟製药公司，也有专注于特定领域的生物技术创新企业，以及专业的契约製造和开发机构。大型製药企业通常利用其广泛的产品线来建立联合治疗，部署全球商业基础设施，并支援大规模的上市后证据项目。相较之下，规模较小的生物技术公司则通常专注于分子层面的创新、生物标记主导的特定适应症，或新型递送平台，这些公司可以与大型公司合作进行后期开发和商业化。

为高阶主管提供可操作的策略建议，以加强临床开发、供应弹性、市场进入和竞争地位。

产业领导者应采取切实可行且优先排序的行动方案，以应对临床开发过程中的复杂性和营运风险。首先，应将临床开发项目与清晰的生物标记策略和适应性试验设计相结合，以便快速识别对治疗有反应的患者亚群，从而缩短开发时间和降低成本。其次，应实现关键原材料供应链多元化，并利用灵活的生产平台来降低关税和物流风险，同时确保产品品质和符合法规要求。第三，应加速研发替代製剂和给药途径（例如皮下给药），以拓宽治疗部位选择并改善病患体验。

研究结果透过稳健的混合方法研究通讯协定检验，该方案结合了公开的临床数据、监管审查、专家访谈和情境压力测试。

本分析的调查方法整合了多种证据来源，以得出可靠且可操作的见解。我们结合了同行评审文献、监管指导文件、临床试验註册数据和上市公司资讯披露，构建了临床进展和监管趋势的全面图景。同时，我们透过与临床医生、生产和物流专家以及市场进入负责人进行专家访谈，获取了有关营运限制和支付方优先事项的定性背景资讯。我们运用资料三角测量和交叉检验程序，确保资料的一致性，并识别出需要进一步研究的不同观点。

免疫查核点抑制剂持续进展的优先投资、营运韧性和证据策略概述

总之，儘管面临许多营运、监管和商业挑战，免疫查核点抑制剂领域仍蕴藏持续的发展机会。联合治疗、基于生物标记的患者筛选以及给药方式的创新正在拓展治疗的可能性，但这需要临床开发、生产和市场进入等各个环节的协调规划。稳健的供应链、明确的区域策略以及能够吸引支付方和临床医生的证据，将是决定哪些专案能够取得持久成功的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：免疫查核点抑制剂市场：依适应症划分

  • 膀胱癌
  • 头颈癌
  • 恶性黑色素瘤
    • 一线治疗
    • 二级治疗
  • 非小细胞肺癌
    • 一线治疗
      • 联合治疗
      • 单药治疗
    • 二级治疗
      • 联合治疗
      • 单药治疗
  • 肾臟细胞癌

第九章：依作用机转分類的免疫查核点抑制剂市场

  • CTLA-4抑制剂
  • PD-1抑制剂
    • 半原发
    • Nivolumab
    • Pembrolizumab
  • PD-L1抑制剂
    • Atezolizumab
    • Avelumab
    • Durvalumab

第十章：免疫查核点抑制剂市场：依给药途径划分

  • 静脉
  • 皮下

第十一章：免疫查核点抑制剂市场：依最终用户划分

  • 门诊手术中心
  • 癌症研究机构
  • 医院
  • 专科诊所

第十二章：免疫查核点抑制剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：免疫查核点抑制剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：免疫查核点抑制剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国免疫查核点抑制剂市场

第十六章：中国免疫疗法查核点抑制剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agenus Inc.
  • Akeso, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • Immutep Ltd.
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merck KGaA
  • NewLink Genetics Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Shanghai Junshi Biosciences Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-FF012EDC38BE

The Immune Checkpoint Inhibitors Market was valued at USD 48.64 billion in 2025 and is projected to grow to USD 52.06 billion in 2026, with a CAGR of 8.19%, reaching USD 84.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.64 billion
Estimated Year [2026] USD 52.06 billion
Forecast Year [2032] USD 84.45 billion
CAGR (%) 8.19%

Comprehensive Executive Introduction Providing Context on Clinical Progress Regulatory Evolution and Strategic Challenges Shaping Immune Checkpoint Therapies

Immuno-oncology has entered an era in which immune checkpoint inhibitors are foundational to treatment paradigms across multiple solid tumor types, and the accompanying commercial and clinical ecosystems are evolving rapidly. This executive introduction synthesizes the contemporary landscape of checkpoint blockade therapies, placing emphasis on clinical milestones, regulatory precedence, and the operational challenges that accompany advanced biologic therapeutics. By framing these elements together, leaders can more clearly appreciate the interconnected dynamics that drive decision-making across development, manufacturing, and commercialization.

The narrative that follows centers on therapies targeting established immune checkpoints and the shifting contours of clinical practice. It highlights how novel combinations, route-of-administration innovations, and diversification of end-user settings are reshaping patient pathways. In addition, it underscores the importance of resilient supply chains, scalable manufacturing platforms, and thoughtful market access strategies to translate clinical efficacy into sustained patient benefit. Ultimately, this introduction prepares readers to interpret deeper analyses that examine segmentation, regional dynamics, company strategies, and policy headwinds that influence the future trajectory of these therapies.

Emerging Scientific, Clinical, Regulatory, and Delivery Innovations That Are Redefining How Immune Checkpoint Inhibitors Are Developed and Utilized

The immune checkpoint inhibitor arena is being reshaped by several transformative shifts that span scientific discovery, clinical practice, and commercial strategy. Advancements in biomarker-driven patient selection and deeper understanding of tumor microenvironment heterogeneity have enabled more precise deployment of PD-1, PD-L1, and CTLA-4 targeted therapies. At the same time, combination regimens that pair checkpoint inhibitors with targeted agents, cytotoxic therapies, or novel immunomodulators are creating new efficacy benchmarks and modifying standard-of-care algorithms. These developments require sponsors and providers to recalibrate trial designs, reimbursement dialogues, and real-world evidence generation.

Concurrently, innovations in formulation and delivery-most notably movement toward subcutaneous dosing where scientifically and clinically feasible-are altering care delivery models and increasing the range of viable end-user settings. This shift supports broader use in specialty clinics and ambulatory surgical centers, while also pressuring hospital-centric infusion models to demonstrate value. Regulatory pathways are adapting to accelerated approvals, tissue-agnostic indications, and more frequent reliance on surrogate endpoints, forcing payers and providers to demand robust post-marketing data. Collectively, these factors are driving a more collaborative industry posture, with alliances, co-development agreements, and cross-sector partnerships becoming central to sustaining long-term competitive advantage.

Analyzing the Possible Aggregated Consequences of 2025 United States Tariff Actions on Biologics Supply Chains Clinical Programs and Access Dynamics

The introduction of new or escalated tariff measures in 2025 has the potential to exert a cumulative influence across the immune checkpoint inhibitor value chain, particularly given the globalized nature of biologics manufacturing and component sourcing. Tariffs on raw materials, single-use consumables, specialized chromatography resins, or capital equipment can increase landed costs for drug substance production and fill-finish operations. When combined with existing logistics constraints and heightened demand for manufacturing capacity, such tariff effects could lengthen lead times, elevate operating expenses, and place a premium on near-term capacity planning.

Beyond direct input cost effects, tariffs can influence strategic supplier selection and geographic footprint decisions. In response, manufacturers may accelerate reshoring or nearshoring initiatives to reduce exposure to tariff risk; however, such transitions require capital investment and time to qualify new facilities and supply chains under regulatory standards. Clinical development programs also confront indirect impacts: higher costs for clinical supplies and ancillary materials could increase trial budgets and necessitate protocol adjustments, while changes in reagent pricing might affect translational work and biomarker analyses. From the payer and provider perspective, any pass-through of increased procurement costs could create tensions during reimbursement negotiations and hospital budgeting cycles, prompting payers to seek cost offsets or stricter utilization criteria.

Mitigation strategies are therefore essential. Manufacturers can pursue diversified sourcing strategies, longer-term supplier contracts, and increased inventory buffers for critical components. They can also invest in modular and flexible manufacturing platforms that allow rapid redeployment across sites. Strategic procurement teams should leverage scenario planning to quantify tariff sensitivities and prioritize investments that deliver resilience, such as dual-sourcing key glycans and adopting single-use systems that reduce capital expenditures. Finally, transparent engagement with regulators and payers about the operational drivers behind cost changes will be important to maintain patient access and to avoid unintended disruptions to care delivery.

Strategically Interpreting Multidimensional Segmentation Across Indication, Mechanism, End User, and Administration Route to Inform Clinical and Commercial Decisions

A segmentation-aware perspective yields the most actionable insights for product strategy, clinical development, and commercial planning in the immune checkpoint inhibitor domain. When evaluating indications, it is critical to recognize that the landscape spans bladder cancer, head and neck cancer, melanoma, non small cell lung cancer, and renal cell carcinoma, with melanoma and non small cell lung cancer further distinguished by first-line and second-line settings and each of those lines able to be subdivided into combination therapy and monotherapy approaches. These indication-level distinctions have immediate implications for trial enrollment criteria, comparator selection, and label positioning, and they shape differential payer expectations across tumor types.

Mechanism-of-action stratification is equally instructive: CTLA-4 inhibitors exemplified by ipilimumab continue to serve as backbone agents in certain combinations, while PD-1 inhibitors such as cemiplimab, nivolumab, and pembrolizumab, alongside PD-L1 inhibitors including atezolizumab, avelumab, and durvalumab, define the majority of current monotherapy and combination strategies. Understanding these pharmacologic classes assists sponsors in designing head-to-head or add-on studies and informs pharmacovigilance priorities. From a delivery and channel perspective, end-user segmentation across ambulatory surgical centers, cancer research institutes, hospitals, and specialty clinics defines logistics, administration workflow, and contracting approaches. Finally, route of administration-primarily intravenous versus subcutaneous-affects patient convenience, site-of-care economics, and formulation development priorities. Integrating these segmentation lenses allows stakeholders to prioritize indications, select appropriate comparators, and craft differentiated value propositions aligned with provider capabilities and patient preferences.

Regional Market Nuances and Strategic Priorities Spanning the Americas Europe Middle East & Africa and Asia Pacific That Determine Launch and Access Approaches

Regional dynamics exert profound influence on clinical trial design, regulatory strategy, manufacturing location decisions, and commercialization pathways. In the Americas, regulatory systems and payer mixes drive a focus on rapid access and differentiated value communications, while production and supply chain resiliency are often calibrated against domestic manufacturing capacity and regulatory expectations. Stakeholders operating in this region typically emphasize clinical endpoints that resonate with local regulators and payers and prioritize real-world evidence programs to support long-term value demonstrations.

Europe, Middle East & Africa present a more heterogeneous set of regulatory frameworks and reimbursement environments, which necessitate adaptive launch sequencing and localized health economic models. Pricing negotiations and health technology assessments in some European jurisdictions require early engagement and evidence generation to justify premium positioning for novel combinations. The Middle East and African markets can offer strategic trial sites and growth opportunities but require tailored access strategies given differing infrastructure and payer landscapes. In the Asia-Pacific region, regulatory pathways are increasingly harmonized, and several markets have accelerated pathways for oncology therapies; however, regional disparities in manufacturing capacity, cold-chain logistics, and reimbursement systems mean that market entry strategies must be carefully prioritized. Across all regions, stakeholders benefit from aligning clinical development plans with locally relevant endpoints, engaging early with payers, and investing in supply chain approaches that support reliable, timely patient access.

Company-Level Competitive Dynamics Highlighting Partnerships Manufacturing Investments and Product Differentiation Strategies in Immuno-oncology

Company strategies within the immune checkpoint inhibitor field are defined by a mix of deep-pocketed pharmaceutical incumbents, focused biotechnology innovators, and specialized contract manufacturing and development organizations. Larger pharmaceuticals often leverage broad pipelines to create combination regimens, deploy global commercial infrastructures, and underwrite extensive post-marketing evidence programs. In contrast, smaller and mid-sized biotechs typically concentrate on molecular innovation, biomarker-driven niche indications, or novel delivery platforms that can be partnered with larger players for late-stage development and commercialization.

Across the ecosystem, partnerships and licensing arrangements are common approaches to accelerate clinical programs and share development risk. Companies are also investing in vertical integration of manufacturing capabilities to control quality and supply timelines, particularly for complex biologics where capacity constraints can disrupt launches. Additionally, there is a discernible push toward platform technologies that enable subcutaneous or less frequent dosing, thereby differentiating offerings on the basis of patient convenience and site-of-care economics. From a talent and operational perspective, organizations that combine deep clinical expertise, regulatory experience, and supply chain agility are better positioned to navigate the evolving competitive landscape and to capitalize on opportunities presented by combination therapies and new dosing paradigms.

Practical Strategic Recommendations for Executives to Strengthen Clinical Development, Supply Resilience, Market Access, and Competitive Positioning

Industry leaders should pursue a set of pragmatic, prioritized actions to succeed amid clinical complexity and operational risk. First, align clinical development programs with clear biomarker strategies and adaptive trial designs that allow fast identification of responsive patient subgroups and reduce the time and cost of development. Second, diversify supply chains for critical raw materials and leverage flexible manufacturing platforms to mitigate tariff and logistics risks while preserving quality and regulatory compliance. Third, accelerate work on alternative formulations and delivery routes, such as subcutaneous options, to broaden site-of-care adoption and improve patient experience.

Additionally, proactive payer engagement and longitudinal evidence generation are essential. Sponsors should design post-approval real-world studies that address endpoints relevant to payers and clinicians, and they should be prepared to support value-based contracting when appropriate. From a commercial perspective, build multidisciplinary launch teams that include clinical account leaders, health economics specialists, and logistics experts to ensure coordinated entry across regions and care settings. Finally, consider strategic alliances that augment in-house capabilities, whether through co-development partnerships, manufacturing collaborations, or targeted acquisitions that fill capability gaps, all while maintaining disciplined portfolio prioritization to focus resources on the most promising therapeutic opportunities.

Robust Mixed Methods Research Protocol Combining Public Clinical Data, Regulatory Review, Expert Interviews, and Scenario Stress Testing to Validate Findings

The underlying methodology for this analysis integrates multiple evidence streams to produce robust, actionable insights. We synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to build a comprehensive view of clinical advances and regulatory trends. In parallel, expert interviews with clinicians, manufacturing and logistics specialists, and market access leaders provided qualitative context around operational constraints and payer priorities. Data triangulation and cross-validation steps were applied to ensure consistency and to surface divergent perspectives that warrant further investigation.

Analytically, we employed scenario-based sensitivity analyses to explore operational risks such as tariff shocks, supply disruptions, and rapid changes in standard-of-care. Attention was given to the practical constraints of biologics manufacturing, including lead times for equipment, qualification timelines for contract manufacturing organizations, and regulatory considerations for process changes. All inputs and assumptions were documented and subjected to internal peer review to maintain transparency and analytical rigor. This layered approach supports informed strategic decision-making without relying on a single source or untested assumption.

Concluding Perspectives on Priority Investments, Operational Resilience, and Evidence Strategies to Enable Sustainable Progress in Immune Checkpoint Therapeutics

In closing, the immune checkpoint inhibitor landscape offers continued opportunity alongside a matrix of operational, regulatory, and commercial challenges. Advances in combination therapies, biomarker-driven patient selection, and delivery innovations are expanding therapeutic potential, yet they require synchronized planning across clinical development, manufacturing, and market access functions. Resilient supply chains, thoughtful regional strategies, and evidence generation that speaks to payers and clinicians will be decisive in determining which programs achieve durable success.

Stakeholders should therefore prioritize investments that enhance development agility, supply reliability, and real-world evidence capabilities. By doing so, organizations can both accelerate patient access to transformative therapies and build sustainable commercial franchises. The synthesis presented here equips leaders with a clear framework to evaluate trade-offs, implement risk mitigation measures, and align internal capabilities with evolving external demands in the immuno-oncology sphere.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immune Checkpoint Inhibitors Market, by Indication

  • 8.1. Bladder Cancer
  • 8.2. Head And Neck Cancer
  • 8.3. Melanoma
    • 8.3.1. First Line
    • 8.3.2. Second Line
  • 8.4. Non Small Cell Lung Cancer
    • 8.4.1. First Line
      • 8.4.1.1. Combination Therapy
      • 8.4.1.2. Monotherapy
    • 8.4.2. Second Line
      • 8.4.2.1. Combination Therapy
      • 8.4.2.2. Monotherapy
  • 8.5. Renal Cell Carcinoma

9. Immune Checkpoint Inhibitors Market, by Mechanism Of Action

  • 9.1. CTLA-4 Inhibitors
  • 9.2. PD-1 Inhibitors
    • 9.2.1. Cemiplimab
    • 9.2.2. Nivolumab
    • 9.2.3. Pembrolizumab
  • 9.3. PD-L1 Inhibitors
    • 9.3.1. Atezolizumab
    • 9.3.2. Avelumab
    • 9.3.3. Durvalumab

10. Immune Checkpoint Inhibitors Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Subcutaneous

11. Immune Checkpoint Inhibitors Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cancer Research Institutes
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Immune Checkpoint Inhibitors Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Immune Checkpoint Inhibitors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Immune Checkpoint Inhibitors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Immune Checkpoint Inhibitors Market

16. China Immune Checkpoint Inhibitors Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agenus Inc.
  • 17.6. Akeso, Inc.
  • 17.7. Amgen Inc.
  • 17.8. Astellas Pharma Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. BeiGene Ltd.
  • 17.11. Bristol-Myers Squibb Company
  • 17.12. Celldex Therapeutics, Inc.
  • 17.13. Coherus BioSciences, Inc.
  • 17.14. Eli Lilly and Company
  • 17.15. Immutep Ltd.
  • 17.16. Incyte Corporation
  • 17.17. Innovent Biologics, Inc.
  • 17.18. Jiangsu Hengrui Medicine Co., Ltd.
  • 17.19. Johnson & Johnson
  • 17.20. Merck & Co., Inc.
  • 17.21. Merck KGaA
  • 17.22. NewLink Genetics Corporation
  • 17.23. Novartis AG
  • 17.24. Pfizer Inc.
  • 17.25. Regeneron Pharmaceuticals, Inc.
  • 17.26. Roche Holding AG
  • 17.27. Sanofi S.A.
  • 17.28. Shanghai Junshi Biosciences Co., Ltd.
  • 17.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 200. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 201. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 233. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 244. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 245. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)